IT Type
Antibody-based IT
Description
The recombinant immunotoxin polypeptides includes a CD3 binding domain and a Pseudomonas exotoxin variant, and particularly include a single-chain (sc) Fv as the CD3 binding moiety. scFv (UCHT-1) -PE38 is used in the treatment of transplant rejection and induction of tolerance, and treating autoimmunity and other immune disorders.
Indication
Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma
Classification
Immuntoxin; biobetter
Construction
scFv (UCHT-1) -PE38
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD3
Full Name
cluster of differentiation 3
Background
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells).
Alternative Names
CD3
Antibody Clone
UCHT1
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Type
scFv
Antibody Indication
Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma
Toxic Moiety
PE38
Organism
Pseudomonas aeruginosa
Family
Pseudomonas exotoxin A
Molecular Mass
38 kDa
Toxic MOA
PE38 is a 38 kDa truncated form of Pseudomonas exotoxin (PE) containing amino acids 253–364 and 381–613. Pseudomonas exotoxin (or exotoxin A) is an exotoxin produced by Pseudomonas aeruginosa. Vibrio cholerae produces a similar protein called Cholix toxin (Q5EK40). It inhibits elongation factor 2. This is achieved by ADP ribosylation of EF2 using NAD +. This then causes the extension of the polypeptide to stop. This mechanism is similar to diphtheria toxin.
The antibody portion mediated selective binding to target cells, while the toxin portion mediated translocation into the cytosol and subsequent cell killing.
Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma
